PDGF in gliomas: More than just a growth factor?

Upsala Journal of Medical Sciences

Volumn 117, Issue 2, 2012, Pages 92-98

  Lindberg, Nanna ^a   Holland, Eric C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Glioma; Growth factor; Oncogene; Oncogenic stress; PDGF B

Indexed keywords

PLATELET DERIVED GROWTH FACTOR;

ARTICLE; BRAIN TUMOR; CELL DIFFERENTIATION; CELL DIVISION; GENETICS; GLIOMA; HUMAN; METABOLISM; ONCOGENE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL DIVISION; GLIOMA; HUMANS; ONCOGENES; PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84859889148     PISSN: 03009734     EISSN: None     Source Type: Journal    
DOI: 10.3109/03009734.2012.654860     Document Type: Article

References (67)

1. Heldin CH, Westermark B, Wasteson A. Platelet-derived growth factor: purification and partial characterization. Proc Natl Acad Sci USA. 1979;76:3722-6. (Pubitemid 9246448)
2. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70:389-99.
3. Pierce GF, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. J Cell Biochem. 1991;45:319-26.
4. Louis DN, Gusella JF. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet. 1995; 11:412-5.
5. Furnari FB, Huang HJ, Cavenee WK. Genetics and malignant progression of human brain tumours. Cancer Surv. 1995;25: 233-75.
6. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oli-goastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001;15:1913-25. (Pubitemid 32738621)
7. Lehti K, Rose NF, Valavaara S, Weiss SJ, Keski-Oja J. MT1-MMP promotes vascular smooth muscle dedifferentiation through LRP1 processing. J Cell Sci. 2009;122:126-35.
8. Aguirre A, Rubio ME, Gallo V. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. Nature. 2010;467:323-7.
9. Lillien L, Raphael HBMP and FGF regulate the development of EGF-responsive neural progenitor cells. Development. 2000;127:4993-5005.
10. Cras-Meneur C, Elghazi L, Czernichow P, Scharfmann R. Epidermal growth factor increases undifferentiated pancreatic embryonic cells in vitro: a balance between proliferation and differentiation. Diabetes. 2001;50:1571-9. (Pubitemid 33639597)
11. Noble M, Barnett SC, Bogler O, Land H, Wolswijk G, Wren D. Control of division and differentiation in oligodendrocyte-type-2 astrocyte progenitor cells. Ciba Found Symp. 1990;150:227-43; discussion 44-9.
12. Bogler O, Wren D, Barnett SC, Land H, Noble M. Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc Natl Acad Sci USA. 1990;87:6368-72.
13. Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P. Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature. 1988;333:560-2.
14. Raff MC, Lillien LE, Richardson WD, Burne JF, Noble MD. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature. 1988;333:562-5.
15. Redwine JM, Armstrong RC. In vivo proliferation of oligo-dendrocyte progenitors expressing PDGFalphaR during early remyelination. J Neurobiol. 1998;37:413-28. (Pubitemid 28506925)
16. Redwine JM, Blinder KL, Armstrong RC. In situ expression of fibroblast growth factor receptors by oligodendrocyte progenitors and oligodendrocytes in adult mouse central nervous system. J Neurosci Res. 1997;50:229-37. (Pubitemid 27473638)
17. Silberstein GB, Daniel CW. Reversible inhibition of mammary gland growth by transforming growth factor-beta. Science. 1987;237:291-3. (Pubitemid 17095150)
18. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76. (Pubitemid 44233629)
19. Lowry WE, Richter L, Yachechko R, Pyle AD, Tchieu J, Sridharan R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci USA. 2008;105:2883-8. (Pubitemid 351723638)
20. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Bio-technol. 2008;26:1276-84.
21. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008;26:1269-75.
22. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature. 2006;441:1068-74. (Pubitemid 43990718)
23. Takuwa N, Fukui Y, Takuwa Y. Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70 (S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol. 1999;19:1346-58. (Pubitemid 29046876)
24. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275:661-5. (Pubitemid 27061332)
25. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-41. (Pubitemid 27456390)
26. Yao R, Cooper GM. Requirement for phosphatidylinositol-3-kinase in the prevention of apoptosis by nerve growth factor. Science. 1995;267:2003-6.
27. Kulik G, Weber MJ. Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I. Mol Cell Biol. 1998;18:6711-18. (Pubitemid 28500558)
28. Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 1997;11:701-13. (Pubitemid 27157159)
29. Araki S, Shimada Y, Kaji K, Hayashi H. Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation. Bio-chem Biophys Res Commun. 1990;168:1194-200. (Pubitemid 20176006)
30. Rawson CL, Loo DT, Duimstra JR, Hedstrom OR, Schmidt EE, Barnes DW. Death of serum-free mouse embryo cells caused by epidermal growth factor deprivation. J Cell Biol. 1991;113:671-80. (Pubitemid 21926023)
31. Jackson EL, Garcia-Verdugo JM, Gil-Perotin S, Roy M, Quinones-Hinojosa A, VandenBerg S, et al. PDGFR alphapositive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron. 2006;51:187-99. (Pubitemid 44063617)
32. Cairns J. Mutation selection and the natural history of cancer. Nature. 1975;255:197-200.
33. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
34. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature. 2005; 434:864-70. (Pubitemid 40558993)
35. Woo RA, Poon RY. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes Dev. 2004;18:1317-30. (Pubitemid 38720599)
36. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907-13. (Pubitemid 40559004)
37. Westermark UK, Lindberg N, Roswall P, Brasater D, Helgadottir HR, Hede SM, et al. RAD51 can inhibit PDGF-B-induced gliomagenesis and genomic instability. Neuro Oncol. 2011;13:1277-87.
38. Westermark B, Nister M, Heldin CH. Growth factors and oncogenes in human malignant glioma. Neurol Clin. 1985;3: 785-99. (Pubitemid 16028838)
39. Doolittle RF, Hunkapiller MW, Hood LE, Devare SG, Robbins KC, Aaronson SA, et al. Simian sarcoma virus onc gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science. 1983;221:275-7. (Pubitemid 13062620)
40. Waterfield MD, Scrace GT, Whittle N, Stroobant P, Johnsson A, Wasteson A, et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature. 1983;304:35-9. (Pubitemid 13063102)
41. King CR, Giese NA, Robbins KC, Aaronson SA. In vitro mutagenesis of the v-sis transforming gene defines functional domains of its growth factor-related product. Proc Natl Acad Sci USA. 1985:82:5295-9. (Pubitemid 15012093)
42. Westermark B, Heldin CH. Platelet-derived growth factor as a mediator of normal and neoplastic cell proliferation. Med Oncol Tumor Pharmacother. 1986;3:177-83. (Pubitemid 17219212)
43. Johnsson A, Heldin CH, Wasteson A, Westermark B, Deuel TF, Huang JS, et al. The c-sis gene encodes a precursor of the B chain of platelet-derived growth factor. EMBO J. 1984;3:921-8.
44. Goustin AS, Leof EB, Shipley GD, Moses HL. Growth factors and cancer. Cancer Res. 1986;46:1015-29. (Pubitemid 16048224)
45. Weinberg RA. The action of oncogenes in the cytoplasm and nucleus. Science. 1985;230:770-6. (Pubitemid 16193966)
46. Deuel TF. Polypeptide growth factors: roles in normal and abnormal cell growth. Annu Rev Cell Biol. 1987;3:443-92.
47. Press RD, Misra A, Samols D, Goldthwait DA, Mapstone TB. Major structural alterations of the c-sis gene are not observed in a series of tumors of the human central nervous system. J Neurooncol. 1989;7:345-56. (Pubitemid 19267996)
48. Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T, et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology. 2004;126:318-21. (Pubitemid 38040746)
49. Pasini B, Matyakhina L, Bei T, Muchow M, Boikos S, Ferrando B, et al. Multiple gastrointestinal stromal and other tumors caused by platelet-derived growth factor receptor alpha gene mutations: a case associated with a germline V561D defect. J Clin Endocrinol Metab. 2007;92:3728-32. (Pubitemid 47435362)
50. de Raedt T, Cools J, Debiec-Rychter M, Brems H, Mentens N, Sciot R, et al. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. Gastroenterology. 2006;131: 1907-12. (Pubitemid 44958505)
51. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, et al. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev. 2010;24:2205-18.
52. Pech M, Gazit A, Arnstein P, Aaronson SA. Generation of fibrosarcomas in vivo by a retrovirus that expresses the normal B chain of platelet-derived growth factor and mimics the alternative splice pattern of the v-sis oncogene. Proc Natl Acad Sci USA. 1989;86:2693-7. (Pubitemid 19112609)
53. UhrbomL, HesselagerG, NisterM, Westermark B.Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998;58: 5275-9. (Pubitemid 28551098)
54. Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, et al. Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia. 2008; 10:1373-82.
55. Tchougounova E, Kastemar M, Brasater D, Holland EC, Westermark B, Uhrbom L. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene. 2007;26:6289-96. (Pubitemid 47462106)
56. Hesselager G, Uhrbom L, Westermark B, Nister M. Complementary effects of platelet-derived growth factor autocrine stimulation and p53 or Ink4a-Arf deletion in a mouse glioma model. Cancer Res. 2003;63:4305-9. (Pubitemid 36950994)
57. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009;101: 1995-2004.
58. Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 2009;15:6258-66.
59. Paulsson J, Lindh MB, Jarvius M, Puputti M, Nister M, Nupponen NN, et al. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer. 2011;128: 1981-8.
60. Holmen SL, Williams BO. Essential role for Ras signaling in glioblastoma maintenance. Cancer Res. 2005;65:8250-5. (Pubitemid 41330589)
61. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400:468-72. (Pubitemid 29361802)
62. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199-207. (Pubitemid 29456888)
63. Druker BJ. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene. 2002;21:8541-6. (Pubitemid 36084186)
64. Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med. 2004;10:1257-60. (Pubitemid 39540445)
65. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, Holland EC. Modeling adult gliomas using RCAS/t-va technology. Transl Oncol. 2009;2:89-95.
66. Hambardzumyan D, Squatrito M, Carbajal E, Holland EC. Glioma formation, cancer stem cells, and akt signaling. Stem Cell Rev. 2008;4:203-10.
67. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.